[{"address1": "12230 El Camino Real", "address2": "Suite 230", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "858 434 1113", "fax": "858 408 3010", "website": "https://www.oncternal.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.", "fullTimeEmployees": 27, "companyOfficers": [{"maxAge": 1, "name": "Dr. James B. Breitmeyer M.D., Ph.D.", "age": 69, "title": "President, CEO & Director", "yearBorn": 1954, "fiscalYear": 2023, "totalPay": 881355, "exercisedValue": 0, "unexercisedValue": 240953}, {"maxAge": 1, "name": "Mr. Richard G. Vincent CPA", "age": 59, "title": "CFO & Treasurer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 602843, "exercisedValue": 0, "unexercisedValue": 84897}, {"maxAge": 1, "name": "Dr. Rajesh  Krishnan Ph.D.", "age": 50, "title": "Chief Technical & Scientific Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Chase C. Leavitt J.D.", "age": 41, "title": "General Counsel & Secretary", "yearBorn": 1982, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Pablo  Urbaneja", "title": "Senior Vice President of Corporate Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://phx.corporate-ir.net/phoenix.zhtml?c=148196&p=irol-IRHome", "maxAge": 86400, "priceHint": 4, "previousClose": 0.694, "open": 0.7, "dayLow": 0.5266, "dayHigh": 0.7, "regularMarketPreviousClose": 0.694, "regularMarketOpen": 0.7, "regularMarketDayLow": 0.5266, "regularMarketDayHigh": 0.7, "forwardPE": -0.05137561, "volume": 644135, "regularMarketVolume": 644135, "averageVolume": 120730, "averageVolume10days": 70215, "averageDailyVolume10Day": 70215, "marketCap": 1558546, "fiftyTwoWeekLow": 0.5266, "fiftyTwoWeekHigh": 13.14, "priceToSalesTrailing12Months": 0.7212152, "fiftyDayAverage": 1.124222, "twoHundredDayAverage": 5.3389835, "currency": "USD", "enterpriseValue": -12828264, "floatShares": 2706683, "sharesOutstanding": 2959640, "sharesShort": 14209, "sharesShortPriorMonth": 16932, "sharesShortPreviousMonthDate": 1728950400, "dateShortInterest": 1731628800, "sharesPercentSharesOut": 0.0047999998, "heldPercentInsiders": 0.0923, "heldPercentInstitutions": 0.12073, "shortRatio": 0.09, "shortPercentOfFloat": 0.005, "impliedSharesOutstanding": 3187840, "bookValue": 3.091, "priceToBook": 0.17036557, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -34575000, "trailingEps": -11.69, "forwardEps": -10.25, "lastSplitFactor": "1:20", "lastSplitDate": 1704672000, "enterpriseToRevenue": -5.936, "52WeekChange": -0.93666106, "SandP52WeekChange": 0.2764505, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ONCT", "underlyingSymbol": "ONCT", "shortName": "Oncternal Therapeutics, Inc.", "longName": "Oncternal Therapeutics, Inc.", "firstTradeDateEpochUtc": 1075818600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "fb3086bb-6779-3bd2-a1c4-93604c12e1a6", "messageBoardId": "finmb_344890993", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.5266, "targetHighPrice": 2.0, "targetLowPrice": 2.0, "targetMeanPrice": 2.0, "targetMedianPrice": 2.0, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 1, "totalCash": 14578000, "totalCashPerShare": 4.925, "totalDebt": 191000, "quickRatio": 2.259, "currentRatio": 2.394, "totalRevenue": 2161000, "debtToEquity": 2.088, "revenuePerShare": 0.73, "returnOnAssets": -0.76448995, "returnOnEquity": -1.49857, "freeCashflow": -17677376, "operatingCashflow": -26632000, "revenueGrowth": 1.76, "operatingMargins": -17.57287, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-15"}]